Members of the ICR’s Discovery Club gathered at The Royal Society to hear about our new five-year research strategy and to mark two years since the opening of our pioneering Centre for Cancer Drug Discovery.

A group of molecules which each simultaneously target two of the most common genetic faults behind an aggressive form of childhood cancer could lead to a potential new drug for the disease, a new ICR study suggests.

Scientists at The Institute of Cancer Research, London in collaboration with a team at the Structural Genomics Consortium in Oxford (SGC) have created a new series of compound that could form the basis for drugs that target the devastating childhood brain cancer diffuse intrinsic pontine glioma, or DIPG.